JP2023093495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023093495A5 JP2023093495A5 JP2023054891A JP2023054891A JP2023093495A5 JP 2023093495 A5 JP2023093495 A5 JP 2023093495A5 JP 2023054891 A JP2023054891 A JP 2023054891A JP 2023054891 A JP2023054891 A JP 2023054891A JP 2023093495 A5 JP2023093495 A5 JP 2023093495A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sequence
- phosphoinositide
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093012A JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15181925 | 2015-08-21 | ||
| EP15181925.7 | 2015-08-21 | ||
| JP2021059383A JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021059383A Division JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093012A Division JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023093495A JP2023093495A (ja) | 2023-07-04 |
| JP2023093495A5 true JP2023093495A5 (enExample) | 2023-11-22 |
Family
ID=54010888
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508728A Active JP6862422B2 (ja) | 2015-08-21 | 2016-08-18 | 組み合わせおよびその使用 |
| JP2021059383A Pending JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
| JP2023054891A Pending JP2023093495A (ja) | 2015-08-21 | 2023-03-30 | 組み合わせおよびその使用 |
| JP2025093012A Pending JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508728A Active JP6862422B2 (ja) | 2015-08-21 | 2016-08-18 | 組み合わせおよびその使用 |
| JP2021059383A Pending JP2021113194A (ja) | 2015-08-21 | 2021-03-31 | 組み合わせおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093012A Pending JP2025131697A (ja) | 2015-08-21 | 2025-06-04 | 組み合わせおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11224654B2 (enExample) |
| EP (2) | EP3337506B1 (enExample) |
| JP (4) | JP6862422B2 (enExample) |
| KR (2) | KR20180042335A (enExample) |
| CN (2) | CN115054697B (enExample) |
| AU (3) | AU2016311136B2 (enExample) |
| CA (1) | CA2995738A1 (enExample) |
| CY (1) | CY1124706T1 (enExample) |
| DK (1) | DK3337506T3 (enExample) |
| ES (1) | ES2891336T3 (enExample) |
| HR (1) | HRP20211291T1 (enExample) |
| HU (1) | HUE056408T2 (enExample) |
| IL (2) | IL257345B2 (enExample) |
| LT (1) | LT3337506T (enExample) |
| MX (2) | MX392561B (enExample) |
| PL (1) | PL3337506T3 (enExample) |
| PT (1) | PT3337506T (enExample) |
| RS (1) | RS62260B1 (enExample) |
| RU (1) | RU2767063C2 (enExample) |
| SI (1) | SI3337506T1 (enExample) |
| SM (1) | SMT202100541T1 (enExample) |
| WO (1) | WO2017032679A1 (enExample) |
| ZA (1) | ZA201801052B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3337506T1 (sl) | 2015-08-21 | 2021-12-31 | Morphosys Ag | Kombinacije in njihove uporabe |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| IL270855B2 (en) | 2017-05-31 | 2023-03-01 | Morphosys Ag | A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax |
| JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル－ドラッグ－ディベロップメント－バイオテック | 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療 |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| AU2020375149A1 (en) * | 2019-10-31 | 2022-05-12 | Incyte Corporation | Sequential anti-CD19 therapy |
| JP2023551519A (ja) * | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 |
| IL313736A (en) * | 2021-12-22 | 2024-08-01 | Incyte Corp | Treatment paradigm for CD19 antibody therapy |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| MXPA02010618A (es) | 2000-04-25 | 2004-05-05 | Icos Corp | Inhibidores de fosfatidilinositol 3-quinasa delta. |
| US20020058029A1 (en) | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080152649A1 (en) * | 2002-03-01 | 2008-06-26 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| PL1761540T3 (pl) | 2004-05-13 | 2017-06-30 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
| JP5825756B2 (ja) * | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| SG173654A1 (en) | 2009-02-23 | 2011-09-29 | Glenmark Pharmaceuticals Sa | Humanized antibodies that bind to cd19 and their uses |
| CA2765080C (en) | 2009-06-24 | 2018-07-17 | The Feinstein Institute For Medical Research | Methods for treating chronic lymphocytic leukemia |
| NZ598732A (en) * | 2009-10-27 | 2014-09-26 | Amgen Res Munich Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| CA2815363C (en) * | 2010-10-22 | 2020-07-14 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| EP2744515B1 (en) * | 2011-08-16 | 2022-02-09 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a nitrogen mustard |
| AP2014007875A0 (en) | 2012-03-05 | 2014-08-31 | Gilead Calistoga Llc | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
| IL291945B2 (en) | 2012-11-01 | 2025-11-01 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US9808753B2 (en) | 2013-02-15 | 2017-11-07 | 3M Innovative Properties Company | System and method for making pleated filter media |
| AU2015277516A1 (en) | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| PL3302550T3 (pl) | 2015-05-26 | 2020-02-28 | Morphosys Ag | Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania |
| SI3337506T1 (sl) | 2015-08-21 | 2021-12-31 | Morphosys Ag | Kombinacije in njihove uporabe |
| SG11201810159TA (en) | 2016-05-30 | 2018-12-28 | Morphosys Ag | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
| CN109415440B (zh) | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| IL270855B2 (en) | 2017-05-31 | 2023-03-01 | Morphosys Ag | A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| JP2022532519A (ja) | 2019-05-03 | 2022-07-15 | モルフォシス・アーゲー | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
| TWI883067B (zh) | 2019-10-31 | 2025-05-11 | 美商英塞特公司 | 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法 |
| AU2020375149A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Sequential anti-CD19 therapy |
| JP7813225B2 (ja) | 2019-10-31 | 2026-02-12 | インサイト・コーポレイション | 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法 |
| CA3181827A1 (en) | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint |
| JP2023551519A (ja) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 |
| CA3204063A1 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| IL313736A (en) | 2021-12-22 | 2024-08-01 | Incyte Corp | Treatment paradigm for CD19 antibody therapy |
-
2016
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Ceased
- 2016-08-18 MX MX2018002241A patent/MX392561B/es unknown
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 CN CN202210502807.XA patent/CN115054697B/zh active Active
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 IL IL297057A patent/IL297057B2/en unknown
- 2016-08-18 SM SM20210541T patent/SMT202100541T1/it unknown
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en not_active Ceased
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 KR KR1020247011695A patent/KR102786010B1/ko active Active
-
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
-
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US12194095B2/en active Active
-
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
-
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en active Pending
- 2024-12-02 US US18/965,167 patent/US20250195646A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093012A patent/JP2025131697A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023093495A5 (enExample) | ||
| RU2017143166A (ru) | Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение | |
| JP2022191301A5 (enExample) | ||
| JP2019533682A5 (enExample) | ||
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| JP2022119854A5 (enExample) | ||
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| RU2018107929A (ru) | Комбинации и их использование | |
| JP2017048208A5 (enExample) | ||
| JP2017528462A5 (enExample) | ||
| JP2017507954A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| JP2019519770A5 (enExample) | ||
| JP2017507953A5 (enExample) | ||
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| PE20160999A1 (es) | Metodos para administrar anticuerpos anti-tnf-alfa | |
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| JP2023055904A5 (enExample) | ||
| RU2010143454A (ru) | Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения не-ходжкинских лимфом | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| JP2019517485A5 (enExample) | ||
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |